Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Vnetni rak dojke - priporočila za diagnostično obdelavo in zdravljenje
Authors:ID Grašič-Kuhar, Cvetka (Author)
ID Hertl, Kristijana (Author)
ID Gazić, Barbara (Author)
ID Majdič, Elga (Author)
ID Žgajnar, Janez (Author)
Files:.pdf PDF - Presentation file, download (380,72 KB)
MD5: 01645A6EAA58C1E47BD51D195967C396
PID: 20.500.12556/dirros/e2f8882e-c9ef-463d-9aed-ecb12fd8bdb2
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:Vnetni rak dojke predstavlja 1 do 5 % raka dojke. Zaradi agresivne narave bolezni sta bistvenega pomena zgodnja diagnoza in začetek zdravljenja. Diagnoza se postavi na podlagi značilnega kliničnega videza (rdečina, edem in/ ali »pomarančna« koža dojke) in histopatološke potrditve diagnoze raka dojke. Zdravljenje je multimodalno. Začetno zdravljenje pri lokalizirani bolezni je sistemska neoadjuvantna kemoterapija z antraciklini in taksani, ki traja 4 do 6 mesecev, sledita modificirana radikalna mastektomija ter dopolnilno obsevanje mamarnega predela in ipsilateralne supraklavikularne lože. Glede na prediktivne dejavnike je indicirano še morebitno zdravljenje z dopolnilnim hormonskim ali biološkim zdravljenjem s trastuzumabom, ki se v kombinaciji s taksani lahko uporablja tudi že v neoadjuvantnem zdravljenju. Kljub multimodalnemu zdravljenju je izid vnetnega raka dojke še vedno slab (srednje preživetje manj kot 4 leta), zato priporočamo zdravljenje v specializiranem onkološkem centru, ki ima izkušnje s tem in kjer je možnost vključevanja v prospektivne mednarodne klinične raziskave.
Keywords:rak (medicina), dojke, diagnostika, zdravljenje
Publication status:Published
Publication version:Version of Record
Year of publishing:2011
Number of pages:str. 98-101
Numbering:Letn. 15, št. 2
PID:20.500.12556/DiRROS-8904 New window
UDC:618.19-006.6-07-08
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-NR0HQACS
COBISS.SI-ID:1196155 New window
Copyright:by Authors
Note:Soavtorji: K. Hertl, B. Gazić, E. Majdič , J. Žgajnar;
Publication date in DiRROS:31.08.2018
Views:3760
Downloads:853
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija. strokovni časopis za zdravnike
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Inflammatory breast cancer – recommendations for diagnosis and treatment
Abstract:Inflammatory breast cancer (IBC) represents 1-5% of all breast cancer. Early and accurate diagnosis of this aggressive disease is of critical importance for the outcome. Diagnosis is made based upon its typical clinical appearance (breast erithema, edema and/or peau d’orange) and histopathological confirmation of invasive cancer. A multimodality approach is recommended for treatment. The initial treatment recommended in a localised disease is primary systemic chemotherapy with anthracyclines and taxanes for a duration of 4-6 months. The surgical treatment of choice is a modified radical mastectomy, followed by adjuvant radiation of the mammary region and ipsilateral supraclavicular region. According to predictive factors, adjuvant hormonal and/or trastuzumab therapy is indicated; the latter could be used in combination with taxanes even in the neoadjuvant setting. Despite the multimodality approach, the outcome of IBC is not optimal (median overall survival in localised disease patients is less than four years). Patients with IBC should be treated in experienced oncological centres with the possibility of cooperation in international randomised clinical studies.


Archive

niGradiv

Back